Nanoparticles give disease-fighting properties to cells
A new biomedical tool has been developed using nanoparticles that deliver transient gene changes to targeted cells...
List view / Grid view
A new biomedical tool has been developed using nanoparticles that deliver transient gene changes to targeted cells...
Researcher have shown how a mRNA molecule known as Lethal-7 serves as a molecular control hub to direct the function of cytotoxic T lymphocytes...
US researchers have conjugated RNA to a molecule of folate, the folate receptor is overexpressed on cancer cells but very low on normal cells, which is why they can target a tumour and avoid healthy cells...
Research reveals cathepsins as potential therapeutic targets in particulate-mediated inflammatory disease…
Pancreatic beta cells help maintain normal blood glucose levels by producing the hormone insulin -- the master regulator of energy (glucose). Impairment and the loss of beta cells interrupts insulin production, leading to type 1 and 2 diabetes.
The molecule microRNA-210 stabilises deposits in the carotid artery and can thus prevent them from tearing, and prevent dangerous blood clots from forming.
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The virus drives production of small molecules, so-called microRNAs, which suppress alarm signals sent out by the infected cell...
22 July 2016 | By Victoria White, Digital Content Producer
Drug Target Review recently caught up with Lorence Kim, Chief Financial Officer of Moderna, to find out more about the company‘s collaboration with Vertex and using mRNA therapeutics to treat patients with cystic fibrosis...
6 July 2016 | By Victoria White, Digital Content Producer
Their collaboration will focus on the use of mRNA therapies to enable cells in the lungs to produce functional copies of the CFTR protein...
21 March 2016 | By Victoria White
Ethris has announced the publication of data that underlines the broad therapeutic potential of the company’s proprietary mRNA transcript therapy platform...